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Objective. Evaluate the incidence of nephrogenic systemic fibrosis (NSF) in patients with liver disease in the peritransplant
period.Materials and Methods. This IRB approved study retrospectively reviewed patients requiring transplantation for cirrhosis,
hepatocellular carcinoma (HCC), or both from 2003 to 2013. Records were reviewed identifying those having gadolinium
enhanced MRI within 1 year of posttransplantation to document degree of liver disease, renal disease, and evidence for NSF.
Results. Gadolinium-enhanced MRI was performed on 312 of 837 patients, including 23 with severe renal failure (GFR <
30mL/min/1.73 cm2) and 289 with GFR > 30. Two of 23 patients with renal failure developed NSF compared to zero NSF cases
in 289 patients with GFR > 30 (0/289; 𝑃 < 0.003). High dose gadodiamide was used in the two NSF cases. There was no increased
incidence of NSF with severe liver disease (1/71) compared to nonsevere liver disease (1/241; 𝑃 = 0.412). Conclusion. Renal disease
is a risk factor for NSF, but in our small sample our evidence suggests liver disease is not an additional risk factor, especially if a
low-risk gadolinium agent is used. Noting that not all patients received high-risk gadolinium, a larger study focusing on patients
receiving high-risk gadolinium is needed to further evaluate NSF risk in liver disease in the peritransplant period.
1. Introduction
Liver transplantation is the optimal treatment for patients
with early-stage hepatocellular carcinoma (HCC) [1–3].
However, because the number of available livers is limited
and does not meet demand, the United Network for Organ
Sharing (UNOS) requires that transplant candidates with
HCC be imaged preoperatively to select ideal candidates for
liver transplantation. Current UNOS guidelines rely primar-
ily on diagnostic imaging to preoperatively diagnose and
stage tumors; preoperative biopsy is not required [4].
In a recent meta-analysis by Colli et al., gadolinium-
enhanced MRI was suggested to be the superior imaging
modality for diagnosing HCC [5]. However, there is a link
between the administration of less stable gadolinium contrast
agents (i.e., gadodiamide) and nephrogenic systemic fibrosis
(NSF) in patients with severe renal failure (glomerular filtra-
tion rate (GFR) < 30mL/min/cm2) [6–10]. Hence, potential
hepatic transplant patients with severe renal insufficiency
may have the benefits of gadolinium-enhancedMRIwithheld
due to concerns for developing NSF. Furthermore, a recently
revoked Food and Drug Administration (FDA) advisory
and mandated package insert labeling on all gadolinium
agents extended the risk from severe renal disease alone to
patients with even mild or moderate renal disease if there is
coexistent liver disease. The warning is still active in Europe
in accordance with the European Medicines Agency (EMA)
guidelines [11]. The warning applies to patients in the periop-
erative liver transplant period and patients with hepatorenal
syndrome. In the absence of data evaluating the association
of liver disease with NSF while controlling for renal disease,
the active EMA warning and historical FDA warning may
result in less imaging, suboptimal imaging, or imaging with
modalities with higher radiation exposure.
The recent meta-analysis by Mazhar et al., reviewing
the NSF literature published between 2000 and 2008 found
that patients with liver disease who develop NSF also have
comorbid severe renal insufficiency but that liver disease
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alone does not confer a risk beyond that of the underlying
renal insufficiency [12]. However, as the authors describe,
the meta-analysis was limited by the summary nature of the
reports, as many articles did not provide sufficient detail to
consistently collect data regarding the nature of each patient’s
liver and kidney disease.
The purpose of our study was to evaluate the risk of
NSF in hepatic transplant patients at a tertiary care liver
transplantation center with 14 reported cases of NSF.
2. Materials and Methods
One author (MP) has patent agreements with GE Healthcare
(Milwaukee, WI), Bracco Diagnostics (Princeton, NJ), Epix
(Lexington, MA), Lantheus (N. Billerica, MA), and Bayer
HealthCare Pharmaceuticals (Berlin, Germany). This retro-
spective, cross-sectional study was performed at a tertiary
liver center and was HIPAA compliant. The investigational
review board approved the study and waived patient consent
requirements.
2.1. Subjects. Gadolinium-enhanced MR imaging is the rou-
tine clinical protocol for HCC surveillance at our institution.
We analyzed records of all patients who underwent liver
transplantation from January 2003 to January 2013. Although
Gadolinium-enhancedMRI enteredmedical practice in 1988,
NSFwas not diagnosed at our institution prior to 2003; hence,
January 2003 was selected as our start date for review.
2.2. Renal Status. Electronic medical records were analyzed
for the number and dates of MRI exams before and after
liver transplant. Patients were excluded if they did not have
a gadolinium-enhanced MRI performed at our institution
within 1 year posttransplantation, as it was our aim to analyze
the risk of NSF in liver disease in the peritransplant period.
We also did not analyze patients with hepatorenal syndrome
because their life expectancy, which varies from 2 weeks to 6
months depending on if they have type 1 or type 2 disease, is
short and thus often those patients do not live long enough to
develop NSF.The estimated glomerular filtration rate (eGFR)
of the included patients was obtained from lab results of
the most recent pre- and/or posttransplant MRI (within one
year of MRI examination date). As awareness of the link
between NSF and less stable gadolinium contrast agents
(i.e., gadodiamide) began to spread in 2006, the practice of
obtaining creatinine values was obtained within 2 weeks of
gadolinium administration, as is the current policy at our
institution [7, 8]. The eGFR was calculated by using the
Modification of Diet in Renal Disease (MDRD) equation
(http://nephron.com/cgi-bin/MDRDSIdefault.cgi). In order
to calculate a Child-Pughes score prior to transplant, the
bilirubin, albumin, International Normalized Ratio (INR),
and degree of ascites and encephalopathy were recorded.
In order to calculate a Model for End Stage Liver Disease
(MELD) score prior to transplant, the bilirubin, INR, and
creatininewere recorded. For patientswhohad been regularly
dialyzed, a creatinine of 4 was used according to UNOS
guidelines [4].
2.3. Determination of NSF. Dermatology and dermatopa-
thology records were reviewed to locate patients with biopsy
confirmed NSF. For each NSF case, the dermatology con-
sultation notes were reviewed to determine the onset and
severity of symptoms. Records were then further reviewed to
determine if each patient had any history of liver disease and
if they were in the peritransplant period. The Child-Pughes,
MELD score, creatinine, and GFR of all NSF patients were
recorded.
2.4. Gadolinium. The administration of gadolinium to these
patients was confirmed by reviewing MR imaging records.
The gadolinium agents administered prior to June 2007
were gadopentetic acid, gadobenate, and gadodiamide. Sub-
sequently thereafter, only gadobenate, gadoteridol, gadoxe-
tate, and gadofosveset were administered at our institution.
Standard dose administrations were based on patient weight
(0.1mmol per kilogram of body weight). High doses of
gadolinium were administered as fixed volumes of 20, 30,
or 40mL for liver MR imaging, which corresponded to
approximately 0.2–0.4mmol/kg. High dose administration
was used routinely from liver MRI prior to July 2006, and
weight-based dosing (0.1mmol/kg) was utilized afterwards.
2.5. Statistical Analyses. Fisher’s exact test was used to exam-
ine whether there were any significant differences in the
presence of NSF in patients with severe chronic kidney
disease (defined as eGFR < 30mL/min/cm2) and in patients
with severe liver disease (defined as Child-Pugh Class C).
Additionally, a subanalysis of patients with severe kidney
disease was performed to assess for any associations with
severe liver disease in this population using Fisher’s exact test.
All 𝑃-values were two-tailed, and a 𝑃-value < 0.05 was
considered significant. Statistical power was also calculated.
Analysis was performed using Statistical Package for Social
Sciences (SPSS) version 20.0 for Microsoft Windows (SPSS
Inc., IL, USA). The R statistical program was also used to
compute the 𝑃-values using Fisher’s exact test for Table 4
and comparing the observed rate of NSF with the published
institutional rate as stated in the discussion [13]. The R
statistical program was also used to compute the upper limit
of a Bayesian credible interval from a binomial distribution
based on the observed rate using the binomial package for R
[14].
3. Results
3.1. Subjects. From January 2003 to January 2013, our insti-
tution performed gadolinium-enhanced MRI exams on 837
transplantation patients. Of these 837 patients (Figure 1),
525 did not receive gadolinium-enhanced MRI within 12
months of transplant andwere excluded.Of the remaining 312
patients (204 men, 108 women; mean age 54 years, range 1–
74: see Table 1), 237 (75.9%) had gadolinium-enhanced MRI
both before and after transplantation, 53 patients (16.9%)
had an MRI only prior to transplantation and 22 only after
transplant (7.1%). A total of 1,742 gadolinium-enhanced MRI
examinations were performed on these 312 patients; 120
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Table 1: Demographics of patients who had undergone liver transplantation with documented GD exposure. Numbers in parenthesis
represent percentages. MELD represents the Model for End Stage Liver disease score average. GFR units equal mL/min/1.73m2.
Demographics of transplant patients with gadolinium-MRI (𝑁 = 312)
Male/female 204/108
Mean age at transplant, yr (±SD) 54.7 (±12)
Mean/median Gd pretransplant time 81/109 days
Mean/median Gd posttransplant time 139/208 days
Mean/median doses of Gd 5.3/5 doses
Number of exams per patient
1–3 120 (38.4)
4–6 91 (29.2)
7 or more 101 (32.4)
Cirrhosis by Child-Pughes score MELD
Class A 142 (45.5) 11.7
Class B 99 (31.7) 22.5
Class C 71 (22.8) 33.7
Renal disease
GFR 0–30 23 (7.4)
GFR 30–59 75 (24.0)
GFR 60–89 109 (34.9)
GFR > 90 105 (33.7)
837 patients underwent liver
transplant for clinical care from
January, 2003 to January, 2013
312 patients had Gd-enhanced MRI
within 12 months of liver transplant
85 patients had Gd-
enhanced MRI with
high risk contrast
agents prior to 2006
227 patients had Gd-
enhanced MRI with
lower risk contrast
agents after 2006
525 did not receive Gd-enhanced MRI
excluded
Patient selection
within 12 months of transplant and were
Figure 1: Flow chart of patient selection. Solid lines specify patients who were included in the study and dotted line specifies patients who
were excluded.
patients (38.5%) had 1–3 MRI exams, 91 patients (29.2%) had
4–6 exams, and 101 patients (32.3%) had 7 or more exams. Of
the 312 patients, 85 underwent MRI with high-risk contrast
agents prior to 2006 and 227 underwent MRI with more
stable contrast agents after 2006.
Patients with liver disease included 164 (52.6%) with
cirrhosis but without HCC, 124 (39.7%) with cirrhosis and
HCC, and 24 (7.7%) with HCC but without cirrhosis. The
median MR imaging to transplant time interval was 109 days
(range of 1–347 days). Child-Pughes scores of the patients
included 142 class A (46%), 99 class B (32%), and 71 class C
(23%). The range of eGFR observed is listed in Table 1. The
associated average MELD score was included in Table 1. Of
the 312 patients, 105 (33.7%) had no renal failure (GFR >
90), 109 (34.9%) had mild renal failure (GFR 60–90), 75
(24.0%) had moderate renal failure (GFR 30–59), and 23
(7.3%) had severe renal failure (GFR < 30 cc/min/1.732).
Patients with severe renal disease had an increased risk
for NSF and patients with severe liver disease did not
(Table 2).
The two patients with liver disease who experienced NSF
both received high doses of gadodiamide.During their course
of multiple MRIs at our institution, patient 1 received a single
high dose (>40mL) and patient 2 received three high doses of
gadodiamide within a one-month span. All other doses were
smaller doses and utilized gadopentetic acid. In total, patient
1 had 1 pretransplant MRI (4 days before surgery) and 2 post-
transplant MRI (shortest interval 13 days after transplant);
patient 2 had 1 pretransplantMRI (12 days before surgery) and
4 posttransplant (shortest interval 358 days after transplant).
Their respective Child-Pughes scores were 12 and 9, MELD
score 42 and 36, and each had serum creatinine and eGFR
of 6.4mg/dL, 13.7mL/min/1.73m2 (dialysis dependent) and
8.3mg/dL, 14.7mL/min/1.73m2 .
4 International Journal of Nephrology
Table 2: NSF and severe renal and severe liver disease. Severe renal disease was found to have a significant association with NSF compared
to nonsevere renal disease. Severe liver disease did not have a significant association with NSF compared to nonsevere liver disease. MELD
represents the Model for End Stage Liver disease score average.
Characteristics NSF negative NSF positive 𝑃 value
Renal disease 0.03
GFR > 30 289 0
GFR 0–29 21 2
Liver disease 0.412
Class A and B (mild/mod.) (MELD avg. 11.7 and 22.5) 241 1
Class C (severe) (MELD avg. 33.7) 69 1
Table 3: In patients with severe renal disease, severe liver disease did not have an association in increasing the risk of NSF. MELD represents
the Model for End Stage Liver disease score average.
Characteristics NSF negative NSF positive 𝑃 value
Severe renal disease 0.998
Class A and B (MELD avg. 11.7 and 22.5) 13 1
Class C (MELD avg. 33.7) 8 1
Table 4: Table 4 demonstrates the association of NSF in patients
with liver disease and varying degrees of renal failure. The mild to
moderate renal group that the Gd warning label targets had 0 cases
of NSF.
Characteristics Patients NSF cases
Liver + no renal disease 183 (58.8%) 0 (0%)
Liver + mild/mod. renal
(GFR 30–90) Dz 106 (34.3%) 0 (0%)
Liver + severe renal Dz
(GFR < 30) 21 (6.9%) 2 (100%)
Total 310 2
3.2. Analysis of Risk Factors. Of the 14 cases of NSF at our
institution, 13 had chronic renal disease; one had acute renal
disease due to acute pancreatitis. Only two of the fourteen
had liver disease. Our study had a standard deviation of
0.079, which yielded a power of 0.71. There was a sig-
nificant association between severe renal disease (GFR <
30mL/min/1.73m2) and NSF (𝑃 = 0.03). The upper limit of
a 95% credible interval for the incidence of NSF in patients
with mild and moderate renal failure was 1.8%. However, no
association between severe liver disease and NSF was present
(𝑃 = 0.41) (Table 2). In patients with severe renal disease,
there is no significant association between NSF and severe
liver disease (𝑃 = 0.998) (Table 3).
4. Discussion
Diagnostic imaging plays a critical role in pretransplantation
staging for HCC. Specifically, transplantation may be expe-
dited in patients with stage T2 tumors based on MR findings
without requiring biopsy. Patients whose tumor burden on
MR exceeds transplantation guidelines will be delisted [15,
16]. This critical role for gadolinium-enhanced MRI may
be obviated by active EMA and historical FDA warnings of
increased NSF risk in patients with liver disease with kidney
disease of any severity [12, 17, 18].
At least three major academic centers report screening
for liver disease in patients who will undergo gadolinium-
enhanced MRI [9, 10]. They cite the historical FDA label and
articles describing an association between liver disease and
NSF [19–21]. One study is a case-report describing a hep-
atitis C liver transplant patient who developed cyclosporine
induced renal failure necessitating dialysis 11 years after
transplant; a second study describes a patient with alpha-
1 antitrypsin related cirrhosis and end stage renal disease
from membranous nephropathy; and a third study describes
a patient with hepatitis B and C cirrhosis status after failed
transplant for portal vein thrombosis with end stage renal
disease requiring hemodialysis [19–21]. All 3 patients had
severe, dialysis-requiring end stage renal disease. These case
reports have identified that NSF occurs in patients with liver
disease but there does not appear to be any published data
establishing liver disease as an independent risk factor.
The suggested association between NSF and liver disease
has legal ramifications as well. Plaintiffs for anti-gadolinium
lawsuits are actively solicited based on a history of prior liver
disease [22]. These developments suggest that a liver disease-
NSF association has gained some acceptance in the absence
of well-controlled, scientifically valid data. The threat of
litigation may lead physicians to avoid gadolinium-enhanced
MRI resulting in suboptimal care for a patient population in
which such imaging plays a critical role.
A recent meta-analysis by Mazhar et al. showed that
amongst 112 articles, only 335 unique NSF cases were
described, of which 41 patients had liver disease. Of these
41, only one did not have severe renal insufficiency (GFR =
34) [23]. Additionally, authors noted that this patient received
nearly 750% of the recommended gadolinium dose in a short
time interval. Within our study, we examined 312 patients
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with liver disease in the peritransplant period, of which
two developed NSF. These two patients received larger than
normal doses of nonionic linear gadolinium and were also in
severe renal failure. However, no cases of NSF were identified
in periliver transplantation patients without severe renal
disease. Furthermore, no statistically significant association
was present between severe and nonsevere liver disease
for the development of NSF. Additionally, a subanalysis of
patients with severe renal disease revealed that severe liver
disease had no significant association with the incidence of
NSF.
A limitation of our study was that determination of
eGFR in patients with cirrhosis is imperfect and may be
overestimated [24]. Calculation of eGFR was based on serum
creatinine, which may be reduced with impaired hepatic
metabolism of creatine to creatinine in hepatic insufficiency.
This may result in a higher apparent rate of NSF in cirrhotic
patients with renal insufficiency classified as nonsevere.
A second limitation given our retrospective study design
was the possible underestimation of the number NSF cases.
We carefully reviewed dermatology/dermatopathology
records, and patients were considered to have NSF only
if biopsy verification was demonstrated. Although to our
knowledge, there were no patients who were suspected of
having NSF based on the dermatology records that did not
undergo skin biopsy. There is an extremely small possibility
that mild cases of NSF may not have been observed by
patients or not believed to be severe enough to warrant
referral to dermatology. If either was the case, then the actual
incidence of NSF may have been higher than that reported.
However, skin disease that is not severe enough or that
does not persist long enough to justify biopsy is not likely
to be clinically significant. Furthermore, patients may have
had dermatology consults outside of our institution, which
would also lead to an underestimation of the number of cases
of NSF, but our transplant patients are followed extremely
closely inside our own institution. Regarding this, there is no
evidence of referrals from outside dermatology centers for
further work-up.
A third limitation of our study was the small number of
patients in our study sample. Only 312 out of our 837 liver
transplant patients were included in the final study popula-
tion to meet our aim of analyzing NSF in the peritransplant
period, which we defined to be within 1 year of transplant.
This small patient size limited the power of our study, which
was 0.71. Although our power was still relatively high, due
to the rare incidence of NSF in the peritransplant period
in our population, an ideal power of 0.8 or higher was not
achieved. However, our institution performs a high number
of gadolinium-enhanced MRIs and has had 14 total cases of
NSF, which is not an insignificant number if the total number
of reported casesworldwide is considered.Therefore, our data
can be considered a strong foundation for future studies and
will likely mirror results of future, larger studies.Thus, future
studies comprised of multicenter, larger patient populations
would be of benefit to increase the power of the study and
corroborate or disprove our conclusions regarding the risk of
NSF in the peritransplant period, especially in patients that
received high-risk gadolinium contrast agents.
Lastly, we did not do an analysis of patients with hep-
atorenal syndrome, as is described in the second part of
the FDA liver disease-related gadolinium warning. This is
because depending on whether a patient has type I or type
II hepatorenal disease, their life expectancy is only 2 weeks
to 6 months [25]. Thus, many patients do not often live
long enough to get NSF. We made a conservative decision to
exclude these patients even though excluding themdecreased
our total number of patients and the power of the study.
However, when comparing our proportion of NSF in
severe renal failure (2/23) within our institutional NSF
database (12/501, as published in Prince et al., [26]), no
statistical significancewas observed after accounting for over-
lap between populations (𝑃 = 0.10). Furthermore, all of
the patients who incurred NSF before 2006 received high
dose linear nonionic gadolinium, which has since been
replaced with ionic and macrocyclic agents [27]. Since 2006,
patients with GFR < 30mL/min/1.73m2 either do not receive
gadoliniumor are dialyzedwithin 24 hours.There are no such
precautions in liver disease patients.
5. Advances in Knowledge
Data at our institution suggests that liver disease confers little
to no association with nephrogenic systemic fibrosis (NSF)
beyond what is expected based upon the underlying renal
function. There have been no cases of NSF since 2006 in
spite of a third of our liver disease patients receiving 7 or
more gadolinium-enhanced MRI examinations in the per-
itransplant period. Our two cases of NSF were in patients
who received high doses of less stable gadodiamide before
2006 and no cases of NSF were identified after 2006 once
our institution switched to more stable gadolinium contrast
agents.
6. Implications for Patient Care
Gadolinium insert warnings, the threat of litigation, and
recent contemporaneous studies may inappropriately deter
physicians from requesting contrast-enhanced MRI exami-
nations in patients with liver disease. This deterrent may be
exaggerated by the fact that traditionally the risk of NSF has
been associated with less stable gadolinium contrast agents
(i.e., gadodiamide), which are currently rarely used in clinical
practice in favor of newer, more stable contrast agents. This
study supports the safety of gadolinium-enhanced MRI in
patients with liver disease in the peritransplant period.
7. Conclusion
In summary, we found in our small sample size that liver
disease confers little to no association with NSF beyond what
is expected based upon the underlying renal function in spite
of a third of our liver disease patients receiving 7 or more
gadolinium-enhanced MRI examinations. The historical
FDA gadolinium related warning, the active EMA warning,
threat of litigation, and recent contemporaneous studies may
inappropriately deter physicians from requesting contrast-
enhanced MRI examinations in patients with liver disease.
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This study supports the safety of gadolinium-enhanced MRI
in patients with liver disease in the peritransplant period,
especially if a low-risk gadolinium agent is used. Noting
that not all patients received high-risk gadolinium contrast
agents, a larger study focusing on patients receiving only
high-risk/less stable gadolinium is needed to further evaluate
the risk of NSF in liver disease in the peritransplant period.
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